GeneCentric Therapeutics has secured $8m in new funding to accelerate the development of its RNA-based liquid biopsy platform, a diagnostic technology aimed at transforming cancer care through non-invasive tumour profiling. The platform is designed to improve treatment selection, monitor disease progression, and detect resistance mechanisms by analysing gene expression signatures from a simple blood draw.
Unlike traditional tissue biopsies, which are invasive and limited by sample availability, GeneCentric鈥檚 liquid biopsy solution offers a dynamic and real-time molecular snapshot of tumour biology. By focusing on RNA rather than DNA, the technology captures active gene expression patterns, enabling more precise, tumour-informed therapeutic decisions.
Graysen Vigneux, medical analyst at GlobalData, commented: 鈥淕eneCentric鈥檚 RNA-based liquid biopsy represents a major innovation in the cancer diagnostics landscape. The ability to track tumour evolution in real time through a blood test provides clinicians with a powerful tool to personalise and adapt treatment strategies, particularly for patients with advanced or metastatic disease.鈥�
RNA-based liquid biopsy provides a complementary approach to DNA-centric methods, offering deeper insight into tumour phenotype and biological behaviour. This enables earlier detection of treatment resistance and facilitates more targeted, responsive care. The core of GeneCentric鈥檚 platform is its proprietary Tumor Functional Taxonomy (TFT) technology, which classifies tumours by RNA expression patterns to support drug response prediction and therapeutic alignment.
GeneCentric鈥檚 platform is currently being positioned for clinical integration and pharmaceutical collaborations. The company plans to use the newly raised funds to expand its biomarker portfolio, support ongoing clinical validation, and pursue regulatory milestones for commercial deployment.
Vigneux added: 鈥淎s the field of precision oncology continues to evolve, RNA-driven diagnostics like GeneCentric鈥檚 liquid biopsy platform will play an increasingly important role. These tools have the potential to redefine how we stratify patients, identify new response pathways, and guide personalised treatments.鈥�
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe successful financing round underscores growing investor confidence in RNA-based diagnostics and reflects a broader trend toward minimally invasive, data-driven solutions in oncology. With this infusion of capital, GeneCentric is positioned to lead a new wave of diagnostic innovation that supports real-time, patient-centric cancer care.
